Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1/2, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Oral Nuvisertib (TP-3654) in Patients With Intermediate or High-Risk Primary or Secondary Myelofibrosis

Next Previous
Trial Profile

A Phase 1/2, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Oral Nuvisertib (TP-3654) in Patients With Intermediate or High-Risk Primary or Secondary Myelofibrosis

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 18 Jun 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Nuvisertib (Primary) ; Momelotinib; Ruxolitinib
  • Indications Essential thrombocythaemia; Myelofibrosis; Polycythaemia vera
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Boston Biomedical; Sumitomo Pharma America; Sumitomo Pharma Oncology; Tolero Pharmaceuticals

Most Recent Events

  • 12 Jun 2025 According to Sumitomo Pharma America media release, the updated preliminary data from this study, presented at the European Hematology Association (EHA) 2025 Congress in Milan, Italy
  • 09 Dec 2024 According to Sumitomo Pharma Media Release, data from this trial presented at the 66th American Society of Hematology (ASH) Annual Meeting & Exposition.
  • 09 Dec 2024 Results published in the Sumitomo Pharma Media Release

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top